Abstract Number: 1192 • 2017 ACR/ARHP Annual Meeting
Patient Characteristics That Predict the Effect of Laparoscopic Adjustable Gastric Band Weight Loss Surgery on Knee Osteoarthritis Pain
Background/Purpose: Obesity is a modifiable risk factor for knee osteoarthritis (OA), yet diet and exercise often fail to achieve sustained weight loss or knee improvement.…Abstract Number: 1193 • 2017 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes
Background/Purpose: CR4056 is a novel imidazoline-2 receptor (I2R) ligand endowed with potent analgesic activities in several and diverse animal models of nociceptive and neuropathic pain,…Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting
Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials
Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling. Bisphosphonates have been touted as disease-modifying agents for OA due to…Abstract Number: 1195 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab in Patients with Knee or Hip Osteoarthritis (NCT01089725)
Background/Purpose : Tanezumab (TNZ) is a monoclonal antibody that inhibits nerve growth factor and reduces hip or knee osteoarthritis (OA) pain. A placebo-controlled phase 3…Abstract Number: 1196 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial
Background/Purpose: Animal studies suggested that inhibiting IL-1α/β with ABT-981 may reduce pain and slow structural progression in OA. This study (NCT02087904; ILLUSTRATE-K) assessed the safety…Abstract Number: 1197 • 2017 ACR/ARHP Annual Meeting
Exploring Determinants Predicting Response to Intra-Articular Hyaluronic Acid Treatment in Symptomatic Knee Osteoarthritis
Background/Purpose: A major challenge regarding intraarticular hyaluronic acid (IAHA) treatment in knee osteoarthritis (OA) is identifying patients who will benefit most. This study aimed to…Abstract Number: 1198 • 2017 ACR/ARHP Annual Meeting
Intra-Articular Hyaluronic Acid Delay to Total Knee Arthroplasty By Number of Injection Courses Received: Analysis of an Administrative Database
Background/Purpose: Total knee arthroplasty (TKA) is the standard surgical treatment for patients with osteoarthritis (OA) that no longer experience symptom relief from conservative or pharmacologic…Abstract Number: 1199 • 2017 ACR/ARHP Annual Meeting
Costs Associated with Osteoarthritis Care Using Intra-Articular Hyaluronic Acid: Analysis of an Administrative Database
Background/Purpose: Many treatment options are available for the management of knee osteoarthritis (OA). The need for non-operative management is motivated by the large costs associated…Abstract Number: 1200 • 2017 ACR/ARHP Annual Meeting
Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo
Background/Purpose: A recent meta-analysis concluded that intra-articular corticosteroids (IACS) for knee osteoarthritis (OA) may be associated with moderate improvement in pain compared with control treatment.1,2…Abstract Number: 1201 • 2017 ACR/ARHP Annual Meeting
Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis
Background/Purpose: Kellgren-Lawrence [KL] radiographic grading is used to classify knee osteoarthritis (OA), but may not accurately reflect disease progression. Classifying subjects by baseline medial joint…Abstract Number: 1202 • 2017 ACR/ARHP Annual Meeting
A Phase 2A, Placebo-Controlled, Randomized Study of ABT-981, an Anti-Interleukin-1Alpha and -1Beta Dual Variable Domain Immunoglobulin, to Treat Erosive Hand Osteoarthritis
Background/Purpose: No approved OA therapies reduce pain and slow joint damage. Mouse data suggested that inhibiting IL-1α and -1β with ABT-981 would reduce pain and…Abstract Number: 1203 • 2017 ACR/ARHP Annual Meeting
Differences in Serum Protein Biomarkers between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients
Background/Purpose: Non-steroidal anti-inflammatory drugs, e.g., celecoxib, are commonly used for inflammatory conditions, including osteoarthritis (OA), but are associated with adverse effects. Combined glucosamine hydrochloride plus…Abstract Number: 1204 • 2017 ACR/ARHP Annual Meeting
Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment
Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, disability and joint deformity due to articular cartilage degradation and bone remodeling. Wnt signaling is involved in…Abstract Number: 1205 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Low-Dose Radiation Therapy on Symptoms in Knee Osteoarthritis: First Results of a Triple Blinded, Randomized Controlled Trial
Background/Purpose: Previous research in animal osteoarthritis (OA) has shown that low-dose radiation therapy (LD-RT) exerts anti-inflammatory effects, but a systematic review concluded that the evidence…Abstract Number: 1206 • 2017 ACR/ARHP Annual Meeting
Chondroitin Sulfate Reduces Pain and Improves Function in Knee Osteoarthritis Significantly Better Than Placebo, Independently of the Definition of Responders
Background/Purpose: In addition to the assessment of the two co-primary endpoints – pain and function – regulatory agencies recommend the use of responder rates in…
ACR Meeting Abstracts